Alglucosidase alfa demonstrates effectiveness and safety in Chinese patients with late-onset Pompe disease: A multi-center prospective study
Authors:
Open Access
- 13 March 2026
- journal article
- research article
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 148 (2) , 109874
Abstract
No abstract availableKeywords
Funding Information
- Sanofi
- Sanofi China Investment Company
This publication has 20 references indexed in Scilit:
- Newborn Screening for 6 Lysosomal Storage Disorders in ChinaJAMA Network Open, 2024
- Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: a systematic review and a meta-analysisJournal of Neurology, 2021
- Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment startJournal of Neurology, 2020
- Long-Term Observation of the Safety and Effectiveness of Enzyme Replacement Therapy in Japanese Patients with Pompe Disease: Results From the Post-marketing SurveillanceNeurology and Therapy, 2019
- Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysisJournal of Neurology, 2016
- Pompe Disease: Diagnosis and Management. Evidence-Based Guidelines from a Canadian Expert PanelCanadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2016
- Effectiveness of enzyme replacement therapy in adults with late‐onset Pompe disease: results from the NCS‐LSD cohort studyJournal of Inherited Metabolic Disease, 2014
- Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfaMolecular Genetics and Metabolism, 2012
- 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapyJournal of Inherited Metabolic Disease, 2012
- Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trialJournal of Neurology, 2009